Innovation can deliver patient-centric, digitally advanced, resilient and sustainable healthcare ‒ a new video series shows what’s possible if the EU seizes this opportunity for transformation.
Greg Rossi discusses the imperative to address cancer in Europe with early detection, precision medicine and equitable access. Stressing the need for urgent action to make cancer a manageable condition, highlighting disparities and the importance of innovation.
The HTA Regulation was intended to streamline how the value of medicines is assessed, but by overburdening the process, it risks making patients wait for new therapies. Now is the time to come together to ensure we can realise the potential of the EU HTA reform for patients.
Like many Europeans, the Dutch feel no love for the European Union. This is a painful but understandable conclusion from a recent study by Ipsos. The EU needs to go to the doctor quickly and get a beating heart full of love because Brussels still seems cold and chilly to the European voter, writes Toine Manders.
Each day, 21 people die while awaiting a transplant in Europe. With the European Parliament Elections approaching, the European Society for Organ Transplantation presents an actionable roadmap for fair and sustainable transformations in the field over the next five years.
Europe’s Critical Medicines Alliance launches today. This is an occasion to reflect on the policy measures that can further enhance access to critical medicines across the EU.
As member states prepare to ramp up the building renovation rate, there is an unprecedented opportunity to hardwire health aspects into the built environment. The brand-new edition of the Healthy Buildings Barometer maps why and how health, energy and climate …
The European Association for the Study of the Liver (EASL) calls on the EU to accelerate public health policies to reduce liver diseases, improve quality of life, and save significant costs.
As Europe enters a new legislative cycle, it charts a decisive course for the future of its life sciences sector, and the wellbeing of its citizens - navigating rapid advances in medical technology, while grappling with systemic healthcare challenges.
Generic medicines extend life-saving treatments to European patients. Neglecting their broader societal value risks hindering care and healthcare system sustainability. In the study Beneath the Surface, we urge policymakers to adapt frameworks to support these medicines and boost access.
This election year, Europe needs to step up action against the silent pandemic of diabetes. Whereas 32 million people in the European Union currently live with diabetes, this figure is set to rise to 33.2 million by 2030.
91 million households in the EU own a pet. That’s 46% of households. Our pets bring blessings we cherish and responsibilities to bear, but what is clear is the joy and companionship our pets bring into the lives of almost half of households in the EU. Our pets are beloved family members, loyal companions, and sources of comfort.
Where a woman lives, her ethnicity and her socioeconomic status all influence her risk of getting cancer, speed of her diagnosis, the treatment she receives and, ultimately, her likelihood of survival. At MSD we are committed to addressing this inequality.
Angelini Pharma's CSO Rafal Kaminski, underscores the rising burden of brain diseases, advocating global attention to brain health. The Headway initiative is presented as a collaborative platform promoting harmonization programs and European guidelines, emphasizing science's crucial role in evidence-based decision-making.
Writing in Euractiv recently, the CEO of the World Brewing Alliance, Justin Kissinger, made some remarkable claims that deserve some scrutiny. He began his piece with a reflection on the failure of the US experiment with alcohol prohibition, and a warning about the continuing influence of the temperance movement over global and national policy approaches to alcohol.
On the 25th Rare Disease Day, three representatives of the rare disease community consider how to maximise the potential of the EU’s Joint Clinical Assessment to accelerate patient access to ATMPs.
This year’s Rare Disease Day (29 February) comes at a critical moment for European rare disease policy. Now more than ever, it’s essential that EU policies enable health equity for people living with rare diseases, says Alexion’s Soraya Bekkali.
The period after a transplant poses significant challenges to patients, among them Graft-Versus-Host-Disease, and the unmet needs of post-transplant care receive limited attention. Together, we can increase awareness and ensure that transplant patients benefit from expanded treatment options and access.
EU pharmaceutical legislation is undergoing a major reform which is an opportunity to increase people’s access to medicines, but worryingly some right-leaning political groups want to give even more power to the pharma industry, writes Monique Goyens, Director General of the European Consumer Organisation (BEUC).
As the world is eager to move on from the COVID-pandemic, the threat of another pandemic, with devastating consequences for all of us, looms large, write Jutta Urpilainen, Stella Kyriakides, Frank Vandenbroucke and others.
Targeted oncology treatments, enabled by biomarker testing, are leading a ‘Renaissance’ in the fight against cancer. To make full use of their potential, we need multi-stakeholder action in overcoming Europe’s testing infrastructure gaps and making testing more accessible.
Finding solutions to address shortages of critical medicines across the EU is a clear priority for the European Commission and the Belgian Presidency of the EU Council, write Stella Kyriakides and Frank Vandenbroucke.
The International Probiotics Association Europe (IPA Europe) is deeply committed to promoting the responsible use of probiotics in food and food supplements. In this statement IPA Europe asks for an evaluation of the current understanding of the term ‘probiotic’ in the EU and to set up clear criteria to prevent the indiscriminate use of the term 'probiotic' and its potential misinterpretation. The full text is available here.
Hungary's Katalin Karikó and Ferenc Krausz claimed 2023 Nobel Prizes, but their success highlights a broader challenge: retaining top talent in Europe. As we celebrate innovators, it's vital to address the "Karikó problem" and support initiatives empowering brilliant minds to flourish in their home countries.
